Research
Metabolic adaptation
Tirzepatide improved glucose control in overweight and obese patients with type 1 diabetes.
Tirzepatide may be beneficial for improving glycemic control in this demographic.
StrongSupportsmedium confidence
HbA1c decreased in the treated group as early as 3 months and was sustained through a 1-year follow-up (−0.67% at 1 year).
Why this rating
Based on study design from abstract.
Source
Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes
Satish K. Garg et al. · Diabetes Technology & Therapeutics · 2024
cohort · n=62Cited 57×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →